Golimumab as First, Second or at Least Third Biologic Agent in Patients With Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis -Post Hoc Analysis of a Non-Interventional Study in Germany

<p>The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).<br></p> <p>© The authors, CC-BY-NC 2020.<b> </b></p>